Skip to main content
. 2020 Dec 5;56(1):90–100. doi: 10.1007/s00535-020-01747-y

Fig. 3.

Fig. 3

Landmark analysis with exclusion of patients who developed HCC recurrence within 3 months (a), 6 months (b), and 9 months (c) after curative therapy. Cumulative incidence of HCC recurrence. The solid line and the dotted line show the untreated group and the DAA group, respectively